A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Calcium and Vitamin D for premenopause
The latest findings from a Cochrane review on the benefit of supplementing premenopausal women with calcium and vitamin D.
Background
Osteoporosis (OP) is characterised by porous...
Informing pharmacy practice with valuable research
PSA’s Pharmacists in 2023 vision advocates the implementation of a ‘research culture’ in Australia. Here’s how members can pursue valuable research in their own...
7CPA: An historic step forward
Last month, I was pleased to be the first PSA President to co-sign a Community Pharmacy Agreement (CPA) on behalf of the profession.
From the President: on the record
PSA is redoubling our efforts to ensure fair remuneration for pharmacists that reflects our training and expertise.
The launch of Pharmacists in 2023 in...
From the President: Valuing our most vulnerable
Pharmacists spending more time on the ground in aged care has become an urgent priority.
It is often said that a measure of civilisation...
Bumetanide for Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia, affecting up to 70% of all people with dementia.1 In the early stages, symptoms can...
